***Background.*** The principal goal of HAART is sustained viral load (VL) suppression resulting in immune reconstitution and a reduction in the risk of AIDS and death. We studied the factors associated with 10 years of continuous VL suppression on HAART in the US Military HIV Natural History Study.

***Methods.*** We evaluated 5721 NHS participants, of which 276 (4.8%) met inclusion criteria. Participants with continuous VL suppression (CS, n = 149) were compared to those who experienced ≥1 virologic failure (VF, n = 127). All participants were required to have ≥1 VL determination each year for \>10 years on HAART and no treatment interruptions \>6 months. VL suppression (\<400 c/mL) within 1 year was required for the CS group and maintained for \>10 years on HAART. VF was defined as 2 consecutive VLs \>400 c/mL after initial suppression. Factors associated with \>10 years of VL suppression were evaluated by multivariate logistic regression.

***Results.*** Compared to the VF group, CS participants at HAART initiation (HI) had higher median CD4 counts (375 cells/uL, IQR 256-499 vs 261 cells/uL, IQR 146-400; P \< 0.001), lower VL (4.4 log~10~ c/mL, IQR 3.5-4.9 vs 4.5 log~10~ c/mL, IQR 3.8-5.0; P = 0.048), and were less likely to start treatment in the early HAART era (66 vs 90%, for years 1996-1999; P \< 0.001). CS participants also had a lower proportion of antiretroviral (ARV) use prior to HAART (37 vs 83%; P \< 0.001), used fewer HAART regimens (3, IQR 2-5 vs 7, IQR 4-9; P \< 0.001), and had a lower proportion of new AIDS events by 10 years of HAART (5 vs 13%; P = 0.032). The factors associated with 10-year VL suppression by multivariate logistic regression included log~10~VL at HI (OR 0.60, 95% CI 0.39, 0.89; P = 0.013), ARV use prior to HI (OR 0.14, 95% CI 0.06, 0.31; P \< 0.001), and number of HAART regimens used (OR 0.72, 95% CI 0.62, 0.82; P \< 0.001). Demographic characteristics, prior AIDS, CD4 at HI, and self-reported adherence were not associated with 10-year VL suppression.

***Conclusion.*** Sustained VL suppression is a key to long-term health in HIV-infected patients, as demonstrated by the lower proportion of AIDS events observed 10 years after HI. The current use of more potent and well-tolerated regimens may mitigate the negative factors of pre-HAART VL and prior ARV use encountered by treatment initiated in the early HAART era.
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